238 related articles for article (PubMed ID: 34555149)
1. Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis.
Nyirjesy P; Schwebke JR; Angulo DA; Harriott IA; Azie NE; Sobel JD
Clin Infect Dis; 2022 Jul; 74(12):2129-2135. PubMed ID: 34555149
[TBL] [Abstract][Full Text] [Related]
2. Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303).
Schwebke JR; Sobel R; Gersten JK; Sussman SA; Lederman SN; Jacobs MA; Chappell BT; Weinstein DL; Moffett AH; Azie NE; Angulo DA; Harriott IA; Borroto-Esoda K; Ghannoum MA; Nyirjesy P; Sobel JD
Clin Infect Dis; 2022 Jun; 74(11):1979-1985. PubMed ID: 34467969
[TBL] [Abstract][Full Text] [Related]
3. Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306.
Goje O; Sobel R; Nyirjesy P; Goldstein SR; Spitzer M; Faught B; Larson S; King T; Azie NE; Angulo D; Sobel JD
J Womens Health (Larchmt); 2023 Feb; 32(2):178-186. PubMed ID: 36255448
[No Abstract] [Full Text] [Related]
4. Ibrexafungerp: A new triterpenoid antifungal.
Sucher AJ; Thai A; Tran C; Mantena N; Noronha A; Chahine EB
Am J Health Syst Pharm; 2022 Dec; 79(24):2208-2221. PubMed ID: 36083109
[TBL] [Abstract][Full Text] [Related]
5. Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy.
Phillips NA; Rocktashel M; Merjanian L
Drug Des Devel Ther; 2023; 17():363-367. PubMed ID: 36785761
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306).
Sobel R; Nyirjesy P; Ghannoum MA; Delchev DA; Azie NE; Angulo D; Harriott IA; Borroto-Esoda K; Sobel JD
BJOG; 2022 Feb; 129(3):412-420. PubMed ID: 34676663
[TBL] [Abstract][Full Text] [Related]
7. Ibrexafungerp in the Treatment of Vulvovaginal Candidiasis.
Barnes KN; Yancey AM; Forinash AB
Ann Pharmacother; 2023 Jan; 57(1):99-106. PubMed ID: 35502451
[TBL] [Abstract][Full Text] [Related]
8. Oral Ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis.
Azie N; Angulo D; Dehn B; Sobel JD
Expert Opin Investig Drugs; 2020 Sep; 29(9):893-900. PubMed ID: 32746636
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of oral ibrexafungerp in Chinese patients with vulvovaginal candidiasis: a phase III, randomized, double-blind study.
Wang X; Wang W; Li J; An R; Chen L; Lin J; Xu D; Qiu J; Song W; Patiman M; Ruan H; Wang G; Xue F; Wang X; Luo X; Ruan Q; Shi L; Zhang C; Hu L; Wang S; Shi H; Wang X; Zhang S; Li Y; Lu J; Wang B; Xu H; Ye H; Zhang B; Zhang C; Qian S; Wu Q; Jia W; Li C; Liao Q
Infection; 2024 Apr; ():. PubMed ID: 38568411
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp.
Grant LM; Orenstein R
J Investig Med High Impact Case Rep; 2022; 10():23247096221123144. PubMed ID: 36059275
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of a single oral 150 mg dose of fluconazole for the treatment of vulvovaginal candidiasis in Japan.
Mikamo H; Matsumizu M; Nakazuru Y; Okayama A; Nagashima M
J Infect Chemother; 2015 Jul; 21(7):520-6. PubMed ID: 25887336
[TBL] [Abstract][Full Text] [Related]
12. Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections.
Martens MG; Maximos B; Degenhardt T; Person K; Curelop S; Ghannoum M; Flynt A; Brand SR
Am J Obstet Gynecol; 2022 Dec; 227(6):880.e1-880.e11. PubMed ID: 35863457
[TBL] [Abstract][Full Text] [Related]
13. Ibrexafungerp for the treatment of vulvovaginal candidiasis.
Sobel JD
Drugs Today (Barc); 2022 Apr; 58(4):149-158. PubMed ID: 35412529
[TBL] [Abstract][Full Text] [Related]
14.
Sobel JD; Borroto-Esoda K; Azie N; Angulo D
Antimicrob Agents Chemother; 2021 Jul; 65(8):e0056221. PubMed ID: 34001513
[TBL] [Abstract][Full Text] [Related]
15. MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis.
Spec A; Pullman J; Thompson GR; Powderly WG; Tobin EH; Vazquez J; Wring SA; Angulo D; Helou S; Pappas PG;
J Antimicrob Chemother; 2019 Oct; 74(10):3056-3062. PubMed ID: 31304536
[TBL] [Abstract][Full Text] [Related]
16. Ibrexafungerp (Brexafemme) for vulvovaginal candidiasis.
Med Lett Drugs Ther; 2021 Sep; 63(1632):141-143. PubMed ID: 34550113
[No Abstract] [Full Text] [Related]
17. A cost-effectiveness analysis of the use of oral ibrexafungerp versus fluconazole for acute vulvovaginal candidiasis in the UK NHS primary care service.
Shah V; Cyril A; Koleoso P; Ragutharan A; Faiz M; Pushpakanthan P
Br J Gen Pract; 2024 Jun; 74(suppl 1):. PubMed ID: 38902100
[TBL] [Abstract][Full Text] [Related]
18. Oteseconazole versus fluconazole for the treatment of severe vulvovaginal candidiasis: a multicenter, randomized, double-blinded, phase 3 trial.
Wang X; Chen L; Ruan H; Xiong Z; Wang W; Qiu J; Song W; Zhang C; Xue F; Qin T; Zhang B; An R; Luo X; Wang W; Zhang S; Cai Y; Kang J; Deng H; Fan S; Cui M; Wang S; Luo X; Su Z; Shu J; Wang Q; Wang F; Bai J; Liao Q
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0077823. PubMed ID: 38095426
[TBL] [Abstract][Full Text] [Related]
19. CD101 Topical Compared With Oral Fluconazole for Acute Vulvovaginal Candidiasis: A Randomized Controlled Trial.
Nyirjesy P; Alessio C; Jandourek A; Lee JD; Sandison T; Sobel JD
J Low Genit Tract Dis; 2019 Jul; 23(3):226-229. PubMed ID: 30893271
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of ibrexafungerp and comparators against Candida albicans genotypes from vaginal samples and blood cultures.
Mesquida A; Vicente T; Reigadas E; Palomo M; Sánchez-Carrillo C; Muñoz P; Guinea J; Escribano P
Clin Microbiol Infect; 2021 Jun; 27(6):915.e5-915.e8. PubMed ID: 33601007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
